US Stock MarketDetailed Quotes

ITRM Iterum Therapeutics

Watchlist

1.2500
0.00000.00%

Close Jul 26 15:59 ET

1.2409
-0.0091-0.73%

Post 16:00 ET

22.49MMarket Cap-473P/E (TTM)

Iterum Therapeutics Stock Forum

Trytosaveabit

Jun 21 07:01

News! Make a note

$Iterum Therapeutics(ITRM.US)$ Iterum Therapeutics PLC - FDA Has Assigned a Pdufa Action Date of October 25, 2024.

Trytosaveabit

May 31 07:05

Make a note

$Iterum Therapeutics(ITRM.US)$ Iterum Therapeutics PLC: FDA Has Assigned a Pdufa Action Date of October 25, 2024.

Jaguar8

May 31 07:01

NEWS

$Iterum Therapeutics(ITRM.US)$
Iterum Therapeutics Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections
Iterum Therapeutics announced that the FDA has accepted the resubmission of its New Drug Application (NDA) for oral sulopenem, aimed at treating uncomplicated urinary tract infections (uUTIs) in adult women. The FDA has assigned a PDUFA action date of October 25, 2024. This milestone follows the REASSURE clinical tria...

Jaguar8

Apr 29 11:38

$Iterum Therapeutics(ITRM.US)$
NEWS
Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem

Trytosaveabit

Mar 28 06:05

Update

$Iterum Therapeutics(ITRM.US)$ Iterum Therapeutics Resubmission of NDA for REASSURE on Track for Early 2Q >ITRM
Dow Jones· 2 mins ago

Stock Region

Mar 7 09:31

Investment Bank Reiterates 'Buy' Rating On Pharmaceutical Company

Iterum Therapeutics: A Sound Investment Amidst Market Volatility?
In today's volatile market, discerning investors are constantly on the lookout for promising ventures that offer a strong return potential. One such opportunity that has piqued interest is Iterum Therapeutics (NASDAQ: $ITRM), a clinical-stage pharmaceutical company focused on developing anti-infectives to combat multi-drug resistant pathogens. Recently, HC Wainwright...

Trytosaveabit

Mar 6 12:55

SWEET! Again you’re welcome! Hehehe

$Iterum Therapeutics(ITRM.US)$ • Ireland-based pharma said it would resubmit its new drug application (NDA) for its oral anti-infective compound, sulopenem, with the FDA in the first half of Q2 2024 sooner than its initial plans.
• The company said that the filing would address the concerns the regulator raised in July 2021 when it declined to approve the product. At the time, the company targeted sulopenem for patients with urinary tract infections caused by quinolone non-susceptible pathogens.
...